Effects of azumolene on normal and malignant hyperthermia-susceptible skeletal muscle

Basic and Clinical Pharmacology and Toxicology

Volumn 102, Issue 3, 2008, Pages 308-316

  Sudo, Roberto Takashi ^a   Carmo, Paula Lima Do ^a   Trachez, Margarete Manhães ^b   Zapata Sudo, Gisele ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AZUMOLENE; CAFFEINE; DANTROLENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; EXTENSOR DIGITORUM LONGUS MUSCLE; GASTROCNEMIUS MUSCLE; GUINEA PIG; HUMAN; HUMAN TISSUE; IC 50; MALE; MALIGNANT HYPERTHERMIA; MOUSE; MUSCLE CONTRACTURE; MUSCLE TWITCH; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SOLEUS MUSCLE;

CAVIA; MAMMALIA; MUS;

EID: 39649105204     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2007.00156.x     Document Type: Article

References (26)

1. Gronert, GA. Malignant hyperthermia. In : Miller RD (ed.). Anesthesia. Churchill-Livingstone, New York, 1986 1971 94.
2. MacLennam DH, Phillips MS. Malignant hyperthermia. Science 1992 256 : 789 94.
3. Sambuughin N, Holley H, Muldoon S et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. Anesthesiology 2005 102 : 515 21.
4. Jurkat-Root K, MacCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000 23 : 4 17.
5. Kolb ME, Horne ML, Martz R. Dantrolene in human MH. Anesthesiology 1982 56 : 254 62.
6. Nelson TE, Lin M, Zapata-Sudo G, Sudo RT. Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel: clinical implications. Anesthesiology 1996 84 : 1368 79.
7. Krause T, Gerbershagen MU, Fiege M, Weihorn R, Wappler F. Dantrolene-A review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004 59 : 364 73.
8. Flewellen EH, Nelson TE, Jones WP, Areans JF, Wagner DL. Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 1993 59 : 275 80.
9. White RL, Wessels FL, Schawan TJ, Ellis KO. 1-[[[5-(substituted phenyl)-2-oxazolyl]-methylene]amino]-2, 4-imidazolidinediones, a new class of skeletal muscle relaxants. J Med Chem 1987 30 : 263 6.
10. 2+] in skeletal muscle fibers from control and malignant hyperthermia - susceptible swine. Anesthesiology 1992 76 : 132 8.
11. 2+ sparks in skeletal muscle fibers. J Pharmacol Exp Ther 2005 314 : 94 102.
12. Mijares AJ, Gerardi A, López JR. EU-4093 does not modify the capacity of calcium uptake by the sarcoplasmatic reticulum. Biophys J 1988 53 : 133a.
13. Dershwitz M, Sreter FA. Azumolene reverses episodes of malignant hyperthermia in susceptible swine. Anesth Analg 1990 70 : 253 5.
14. Trachez MM, Zapata-Sudo G, Moreira OR, Chedid NG, Russo VF, Sudo RT. Motor nerve blockade potency and toxicity of non-racemic bupivacaine in rats. Acta Anaesthesiol Scand 2005 49 : 66 71.
15. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998 88 : 579 88.
16. Paul-Pletzer K, Yamamoto T, Bhat MB et al. Identification of a dantrolene-binding sequence on the skeletal muscle on the ryanodine receptor. J Biol Chem 2002 277 : 34918 23.
17. 2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem 1997 272 : 26965 71.
18. Prostasi F, Paolini C, Nakai J, Beam KG, Franzini-Armostrong C, Allen PD. Multiple regions of RyR1 mediate functional and structural interactions with alpha (1s)-dihydropyridine receptors in skeletal muscle. Biophys J 2002 83 : 3230 44.
19. Lu X, Xu L, Meissner G. Activation of the skeletal muscle calcium release channel by a cytoplasmatic loop of the dihydropyridine receptor. J Biol Chem 1994 269 : 6511 6.
20. Flewellen EH, Nelson TE. Prophylactic and therapeutic doses of dantrolene for malignant hyperthermia. Anesthesiology 1984 61 : 477.
21. Leslie GC, Part NJ. The action of dantrolene sodium on rat fast and slow muscle in vivo. Br J Pharmacol 1981 72 : 665 72.
22. Rousseau E, Ladine J, Liu QY, Meissner G. Activation of the release channel of skeletal muscle sarcoplasmic reticulum by caffeine and related compounds. Arch Biochem Biophys 1988 267 : 75 86.
23. Ellis FR, Harriman DG. A new screening test for susceptible to malignant hyperpyrexia. Br J Anaesth 1973 45 : 638.
24. Sudo RT, Nelson TE. Changes in ryanodine-induced contractures by stimulus frequency in malignant hyperthermia susceptible and malignant hyperthermia nonsusceptible dog skeletal muscle. J Pharmacol Exp Ther 1997 282 : 1331 6.
25. Ellis KO, Wessels FL, Carpenter JF. Effects of intravenous dantrolene sodium on respiratory and cardiovascular functions. J Pharm Sci 1976 65 : 1359 64.
26. Ellis KO, Butterfield JL, Wessels FL, Carpenter JF. A comparasion of skeletal, cardiac, and smooth muscle actions of dantrolene sodium-a skeletal muscle relaxant. Arch Int Pharmacodyn Ther 1976 224 : 118 32.